ECSP15030460A - Composición de difenidol de liberación prolongada - Google Patents

Composición de difenidol de liberación prolongada

Info

Publication number
ECSP15030460A
ECSP15030460A ECIEPI201530460A ECPI201530460A ECSP15030460A EC SP15030460 A ECSP15030460 A EC SP15030460A EC IEPI201530460 A ECIEPI201530460 A EC IEPI201530460A EC PI201530460 A ECPI201530460 A EC PI201530460A EC SP15030460 A ECSP15030460 A EC SP15030460A
Authority
EC
Ecuador
Prior art keywords
release
agents
composition
difenidol
long
Prior art date
Application number
ECIEPI201530460A
Other languages
English (en)
Inventor
Hernández Guadalupe Resendiz
Original Assignee
Invekra S A P I De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invekra S A P I De C V filed Critical Invekra S A P I De C V
Publication of ECSP15030460A publication Critical patent/ECSP15030460A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una composición farmacéutica de difenidol de liberación prolongada que comprende: a) de 15 a 50% de clorhidrato de difenidol; b) de 0.1 a 20% de uno o más agentes aglutinantes; c) de 5 a 90% de uno o más agentes diluentes; d) de 5 a 50% de uno o más agentes modificadores de la liberación; e) de 0.25 a 10% de uno o más agentes lubricantes; y f) 0.1 a 10% de agentes deslizantes. De manera preferida, esta composición farmacéutica se administra por vía oral y se encuentra en forma de tableta.
ECIEPI201530460A 2013-01-16 2015-07-15 Composición de difenidol de liberación prolongada ECSP15030460A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2013000662A MX356789B (es) 2013-01-16 2013-01-16 Composición de difenidol de liberación prolongada.

Publications (1)

Publication Number Publication Date
ECSP15030460A true ECSP15030460A (es) 2017-08-31

Family

ID=51209070

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201530460A ECSP15030460A (es) 2013-01-16 2015-07-15 Composición de difenidol de liberación prolongada

Country Status (11)

Country Link
US (1) US10188610B2 (es)
BR (1) BR112015011351B1 (es)
CA (1) CA2889283C (es)
CL (1) CL2015001128A1 (es)
CR (1) CR20150275A (es)
DO (1) DOP2015000089A (es)
EC (1) ECSP15030460A (es)
GT (1) GT201500038A (es)
MX (1) MX356789B (es)
PE (1) PE20150888A1 (es)
WO (1) WO2014111799A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108283625A (zh) * 2018-04-26 2018-07-17 江苏四环生物制药有限公司 一种盐酸地芬尼多片的制备方法
CN110638775A (zh) * 2019-10-25 2020-01-03 仁和堂药业有限公司 一种盐酸地芬尼多片剂及其应用
CN110638776A (zh) * 2019-10-25 2020-01-03 仁和堂药业有限公司 盐酸地芬尼多片的制备工艺
CN110934842A (zh) * 2019-11-26 2020-03-31 卓和药业集团有限公司 盐酸地芬尼多片的制备方法
CN112315925A (zh) * 2020-11-16 2021-02-05 仁和堂药业有限公司 盐酸米安色林片及其制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
ATE119766T1 (de) * 1989-10-26 1995-04-15 Nippon Shinyaku Co Ltd Zubereitung für den magen.
CN1935140A (zh) 2005-09-19 2007-03-28 长沙佰川医药科技开发有限责任公司 复方盐酸地芬尼多分散片剂及其制备方法
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US8574625B2 (en) * 2007-05-30 2013-11-05 Wockhardt Ltd. Tablet dosage form
KR101051630B1 (ko) * 2008-10-02 2011-07-26 한국유나이티드제약 주식회사 용출률과 복용편의성이 향상된 트리메부틴 서방정
KR20110117216A (ko) * 2009-03-03 2011-10-26 제노포트 인코포레이티드 Ｒ-바클로펜 전구약물의 서방형 경구 투약 형태

Also Published As

Publication number Publication date
BR112015011351A2 (pt) 2017-07-11
CA2889283A1 (en) 2014-07-24
CL2015001128A1 (es) 2015-10-09
GT201500038A (es) 2019-08-02
BR112015011351B1 (pt) 2021-11-23
PE20150888A1 (es) 2015-06-08
MX356789B (es) 2018-06-12
US20150352051A1 (en) 2015-12-10
US10188610B2 (en) 2019-01-29
WO2014111799A1 (es) 2014-07-24
MX2013000662A (es) 2014-07-16
CR20150275A (es) 2015-07-08
CA2889283C (en) 2020-12-29
DOP2015000089A (es) 2015-05-15

Similar Documents

Publication Publication Date Title
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
CL2016001547A1 (es) Composiciones para el cuidado oral
ECSP15030460A (es) Composición de difenidol de liberación prolongada
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
DOP2015000183A (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
AR091465A1 (es) Una composicion farmaceutica que contiene acido nicotinico y/o nicotinamida y/o triptofano para influenciar positivamente la microbiota intestinal
GT201300309A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
PE20142284A1 (es) Procedimiento de fabricacion de una forma de dosificacion farmaceutica que comprende nifedipina y candesartan cilexetilo
GT201200284A (es) Composición farmacéutica
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2015001940A1 (es) Formulación que comprende un compuesto de benzotiazolona.
BR112015028025A2 (pt) composição farmacêutica adaptada para administração oral e regime de tratamento para o controle de insuficiência adrenal
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
AR092570A1 (es) Composicion oral que contiene dapoxetina como base libre
UA107884C2 (en) Combined anti-tuberculosis drug
CN302586546S (zh) 钻
CN302524948S (zh) 瓶子
TH1501001478A (th) องค์ประกอบทางเภสัชกรรมสำหรับการให้ทางปากซึ่งมีการละลาย และ/หรือ การดูดซึมดีขึ้น
CN302042043S (zh) 滑道式定位仪(rst-bdsl50a)
CN302542913S (zh) 显示器
CN302150118S (zh) 班台
CN302112526S (zh) 连体马桶
CN302175352S (zh) 用于钻杆的电子标签
TH173412A (th) องค์ประกอบดูแลช่องปาก
CN302192320S (zh) 墙体砌块(一)